Evidence map›Paper›PMID 38782835›Full record

ArticleMolecular and cellular biochemistry2025

A new gold(I) phosphine complex induces apoptosis in prostate cancer cells by increasing reactive oxygen species.

Yuan Wang, Haokun Yuan, Ruiqin Fang, Junzhu Lu, Jiaqi Duo, Ge Li, Wei-Jia Wang

Abstract read
PubMed Publisher
In one paragraph

Article in Molecular and cellular biochemistry, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Article
  2. A dual inhibitor of TrxR1 and XIAP induces pyroptosis in melanoma.Frontiers in cell and developmental biology · 2025
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

Yuan WangThe Key Laboratory for Human Disease Gene Study of Sichuan Province and the Department of Laboratory Medicine, School of Medicine, Sichuan Provincial People's Hospital, University of Electronic Science and Technology of China, Chengdu, China. wangyuan_med@uestc.edu.cn.
Haokun YuanThe School of Medicine, University of Electronic Science and Technology of China, Chengdu, China.
Ruiqin FangThe School of Life Science, University of Electronic Science and Technology of China, Chengdu, China.
Junzhu LuThe School of Medicine, University of Electronic Science and Technology of China, Chengdu, China.
Jiaqi DuoThe School of Medicine, University of Electronic Science and Technology of China, Chengdu, China.
Ge LiThe School of Medicine, University of Electronic Science and Technology of China, Chengdu, China.
Wei-Jia WangThe Key Laboratory for Human Disease Gene Study of Sichuan Province and the Department of Laboratory Medicine, School of Medicine, Sichuan Provincial People's Hospital, University of Electronic Science and Technology of China, Chengdu, China. wangwj@xmu.edu.cn.

Funding

Fundamental Research Funds for the Central Universities Y030222059002005The Department of Science and Technology of Sichuan Province 2021ZYD0092The National Natural Science Foundation of China 82072727
6 · The paper itself

Abstract

Thioredoxin reductase (TrxR) is a pivotal regulator of redox homeostasis. It is frequently overexpressed in various cancer cells, including prostate cancer, making it a promising target for the development of anti-cancer drugs. In this study, we screened a series of newly designed complexes of gold(I) phosphine. Specifically, Compound 5 exhibited the highest cytotoxicity against prostate cancer cells and demonstrated stronger antitumor effects than commonly used drugs, such as cisplatin and auranofin. Importantly, our mechanistic study revealed that Compound 5 effectively inhibits the TrxR system in vitro. Additionally, Compound 5 promoted intracellular accumulation of reactive oxygen species (ROS), leading to mitochondrial dysfunction and irreversible apoptosis in prostate cancer cells. Our in vivo xenograft study further demonstrated that Compound 5 has excellent antitumor activity against prostate cancer cells, but does not cause severe side effects. These findings provide a promising lead Compound for the development of novel antitumor agents targeting prostate cancer and offer a valuable tool for investigating biological pathways involving TrxR and ROS modulation.

Indexed as

Antineoplastic AgentsApoptosisGoldPhosphinesProstatic NeoplasmsReactive Oxygen SpeciesAnimalsCell Line, TumorHumansMaleMiceMice, NudeThioredoxin-Disulfide ReductaseXenograft Model Antitumor AssaysAntineoplastic AgentsGoldphosphinePhosphinesReactive Oxygen SpeciesThioredoxin-Disulfide ReductaseApoptosisGold(I) complexProstate cancerReactive oxygen speciesTrxR

Identifiers

PMID38782835

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.